Exploring current and emerging therapies for porphyrias
Liver International · 2024
DOI: 10.1111/liv.15979 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Liver International, 2024. Verfasst von Daniel Jericó und 7 weiteren Autor:innen. Beteiligte Einrichtung: Solid Tumors Program, Hepatology: Porphyrias & Carcinogenesis Laboratory, CIMA-University of Navarra, Pamplona, Spain. Hauptthemen laut MEDLINE: Drug Delivery Systems. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Spanish Institute of Health Carlos III, Fundación Mutua Madrileña, Fundación Eugenio Rodríguez Pascual.
Abstract (Originalsprache)
Porphyrias are rare, mostly inherited disorders resulting from altered activity of specific enzymes in the haem synthesis pathway that lead to accumulation of pathway intermediates. Photocutaneous symptoms occur when excess amounts of photoreactive porphyrins circulate in the blood to the skin, whereas increases in potentially neurotoxic porphyrin precursors are associated with neurovisceral symptoms. Current therapies are suboptimal and their mechanisms are not well established. As described here, emerging therapies address underlying disease mechanisms by introducing a gene, RNA or other specific molecule with the potential to cure or slow progression of the disease. Recent progress in nanotechnology and nanoscience, particularly regarding particle design and formulation, is expanding disease targets. More secure and efficient drug delivery systems have extended our toolbox for transferring specific molecules, especially into hepatocytes, and led to proof‐of‐concept studies in animal models. Repurposing existing drugs as molecular chaperones or haem synthesis inhibitors is also promising. This review summarizes key examples of these emerging therapeutic approaches and their application for hepatic and erythropoietic porphyrias.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Solid Tumors Program, Hepatology: Porphyrias & Carcinogenesis Laboratory, CIMA-University of Navarra, Pamplona, Spain.
- Department of Internal Medicine, Reference Center for Inherited Metabolic Disease-MetabERN, University Hospital 12 de Octubre, UCM, Madrid, Spain.
- Porphyria Laboratory and Center, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA.
- French Porphyria Reference Center (CRMR Porphyries France), Université Paris, Paris, France.
- Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
ORCID-Profile: Daniel Jericó, Karol M Córdoba, Francesco Urigo, Rafael Enríquez de Salamanca, Karl E Anderson, Jean-Charles Deybach, Matías A Ávila, Antonio Fontanellas
Förderung
- Spanish Institute of Health Carlos III
- Fundación Mutua Madrileña
- Fundación Eugenio Rodríguez Pascual
Zitieren
APA
Jericó, D., Córdoba, K. M., Urigo, F., Enríquez de Salamanca, R., Anderson, K. E., Deybach, J. C., Ávila, M. A., & Fontanellas, A. (2024). Exploring current and emerging therapies for porphyrias. Liver International. https://doi.org/10.1111/liv.15979
Vancouver
Jericó D, Córdoba KM, Urigo F, Enríquez de Salamanca R, Anderson KE, Deybach JC, et al. Exploring current and emerging therapies for porphyrias. Liver International. 2024. doi:10.1111/liv.15979
BibTeX
@article{Jeric2024,
author = {Jericó, Daniel and Córdoba, Karol M and Urigo, Francesco and Enríquez de Salamanca, Rafael and Anderson, Karl E and Deybach, Jean-Charles and Ávila, Matías A and Fontanellas, Antonio},
title = {Exploring current and emerging therapies for porphyrias},
journal = {Liver International},
year = {2024},
doi = {10.1111/liv.15979}
}
EUVIMED